Company profile: Notable
1.1 - Company Overview
Company description
- Provider of personalized drug combination testing for cancer patients and a Predictive Medicine Platform (PMP) that predicts patient response to specific therapies to identify responsive patients before treatment. Develops therapeutics, including Presponse Therapeutics and the PLK-1 inhibitor volasertib, with development guided by predictive patient response data.
Products and services
- Predictive Medicine Platform (PMP): Engineers a patient-specific platform that predicts individual response to specific cancer therapies, identifying and selecting responsive patients before treatment, informing personalized drug combination testing decisions
- Presponse™ Therapeutics: Architects pre-treatment therapeutics designed to predict patient benefit from cancer treatments before therapy initiation, enabling selection of responsive patients and personalized regimen planning
- Volasertib: A PLK-1–targeted inhibitor used in treating acute myeloid leukemia and other tumors, with development guided by predictive patient response data to select responsive patients before therapy.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Notable
Profound Medical
HQ: Canada
Website
- Description: Provider of medical device solutions for MRI-guided ablation in prostate care, offering TULSA-PRO, a transurethral ultrasound ablation system under MRI guidance; Sonalleve, a HIFU therapy platform for non-invasive treatment of uterine fibroids and palliative bone metastases pain; and PRO-Talk, an educational platform with learning resources for physicians.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Profound Medical company profile →
Dren Bio
HQ: United States
Website
- Description: Provider of protein engineering technologies for depleting cells, protein aggregates, and other disease-causing agents. Develops antibody therapeutics including DR-01, a fully human, nonfucosylated ADCC-inducing antibody for hematologic malignancies and autoimmune disorders, and a Targeted Myeloid Engager and Phagocytosis Platform with DR-0201 for B cell malignancies and DR-0202 for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dren Bio company profile →
Symphogen
HQ: Denmark
Website
- Description: Provider of recombinant polyclonal antibody drugs and platforms for disease treatment and prevention. Offers Symplex PCR cloning for antigen-specific antibodies, an antibody discovery and research platform focused on oncology and immuno-oncology, and CMC processes for manufacturing. Pipeline includes Sym013 (pan-HER antibody mixture) and Sym021 (anti-PD-1) with combinations Sym022 (anti-LAG-3) and Sym023 (anti-TIM-3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Symphogen company profile →
Revolution Medicines
HQ: United States
Website
- Description: Provider of RAS(ON) inhibitors for RAS-addicted cancers, including RMC-6236 (multi-selective), RMC-6291 (G12C-selective), and RMC-9805 (G12D-selective); and a tri-complex inhibitor platform enabling creation of inhibitors that target the active state of RAS proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revolution Medicines company profile →
Intellikine
HQ: United States
Website
- Description: Provider of discovery and development of orally available small-molecule therapies targeting the PI3K/Akt/mTOR pathway, building a discovery platform to rapidly generate kinase inhibitor drug candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intellikine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Notable
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Notable
2.2 - Growth funds investing in similar companies to Notable
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Notable
4.2 - Public trading comparable groups for Notable
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →